Ballentine Partners’s Genmab GMAB Stock Holding History

Ballentine Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,929	Closed	-$213K	–	1053
2025 Q4	$213K	Buy	+6,929	New	+$216K	﹤0.01%	897

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ballentine Partners's GMAB Position: Q1 2026 in Review

Ballentine Partners sold out of Genmab (GMAB) in Q1 2026, closing a stake of 6,929 shares — an estimated $213K sold.

Ballentine Partners first reported a position in GMAB in Q4 2025 and held it in 1 quarter. The position peaked at $213K in Q4 2025. 273 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Ballentine Partners reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
Ballentine Partners sold 6,929 Genmab shares in Q1 2026, an estimated $213K.
Ballentine Partners first reported a position in Genmab in Q4 2025 and held it in 1 quarter.
Ballentine Partners's Genmab position peaked at $213K in Q4 2025.
273 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Ballentine Partners's 13F filing for Q1 2026, filed 14 May 2026.